Did you mean: (ReoPro 0 625 5)?
- Postmenopausal hormone treatment alters neural pathways but does not improve verbal cognitive function. [Journal Article]Menopause 2018; 25(12):1424-1431M
- CONCLUSIONS: Although current and past hormone treatment was associated with differences in neural pathways used during verbal discrimination, verbal function was not higher than never-users.
- Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. [Randomized Controlled Trial]JAMA Oncol 2015; 1(3):296-305JO
- CONCLUSIONS: In the E + P trial, the higher breast cancer risk seen during intervention was followed by a substantial drop in risk in the early postintervention phase, but a higher breast cancer risk remained during the late postintervention follow-up. In the estrogen alone trial, the lower breast cancer risk seen during intervention was sustained in the early postintervention phase but was not evident during the late postintervention follow-up.
- Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. [Randomized Controlled Trial]JAMA 2010; 304(15):1684-92JAMA
- CONCLUSIONS: Estrogen plus progestin was associated with greater breast cancer incidence, and the cancers are more commonly node-positive. Breast cancer mortality also appears to be increased with combined use of estrogen plus progestin.
- Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials. [Randomized Controlled Trial]Arch Intern Med 2010; 170(18):1678-85AI
- CONCLUSIONS: These data suggest that estrogen therapy increases the risk of nephrolithiasis in healthy postmenopausal women. These findings should be considered in decision making regarding postmenopausal estrogen use. The mechanisms underlying this higher susceptibility remain to be determined. Trial Registration clinicaltrials.gov Identifier: NCT0000611.
- Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. [Randomized Controlled Trial]Epilepsia 2006; 47(9):1447-51E
- CONCLUSIONS: CEE/MPA is associated with a dose-related increase in seizure frequency in postmenopausal women with epilepsy. CEE/MPA may decrease lamotrigine levels.
- Effect of vitamin E supplementation with and without hormone therapy on circulatory inflammatory markers in postmenopausal women. [Randomized Controlled Trial]Fertil Steril 2006; 85(3):667-73FS
- CONCLUSIONS: Vitamin E attenuated C-reactive protein increases in postmenopausal women treated with estrogen replacement therapy but not with HT. Because there was no other persistent effect on six additional inflammatory markers, it can be concluded that vitamin E and HT do not play a major role in promoting a change in cardiovascular inflammatory markers.
- Transdermal progesterone cream as an alternative progestin in hormone therapy. [Randomized Controlled Trial]Altern Ther Health Med 2005 Nov-Dec; 11(6):36-8AT
- CONCLUSIONS: Patients preferred transdermal PC over oral MPA. This preliminary data indicate that CEE/PC has a similar effect on the endometrium as standard oral HT over a 6-month period.
- Estrogen plus progestin and the risk of coronary heart disease. [Randomized Controlled Trial]N Engl J Med 2003; 349(6):523-34NEJM
- CONCLUSIONS: Estrogen plus progestin does not confer cardiac protection and may increase the risk of CHD among generally healthy postmenopausal women, especially during the first year after the initiation of hormone use. This treatment should not be prescribed for the prevention of cardiovascular disease.
- Impact of WHI conclusions and ACOG guidelines on clinical practice. [Review]Int J Fertil Womens Med 2003 May-Jun; 48(3):106-10; discussion 137-8IJ
- This past July, the community of physicians practicing obstetrics/gynecology and women's medicine was startled by a paper in the Journal of the American Medical Association, which reported data from one arm of the Women's Health Initiative (WHI). The major finding was that the group of subjects undergoing treatment with combined HRT in the form of Prempro (0.625 mg/day conjugated equine estrogens…
This past July, the community of physicians practicing obstetrics/gynecology and women's medicine was startled by a paper in the Journal of the American Medical Association, which reported data from one arm of the Women's Health Initiative (WHI). The major finding was that the group of subjects undergoing treatment with combined HRT in the form of Prempro (0.625 mg/day conjugated equine estrogens (CEE) + 2.5 mg/day medroxyprogesterone acetate) was found to have increased risk of breast cancer and no apparent cardiac benefit. Although several benefits were considered, the likely result to be realized by 8 years, interim findings by the study's safety committee at 5 years were deemed sufficiently troubling to stop this arm of the trial at 5.2 years. Reaction was mixed. This paper places findings into a clinical perspective and considers their effect on the practice guidelines of relevant professional organizations.
New Search Next
- Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. [Randomized Controlled Trial]Am J Obstet Gynecol 2003; 188(1):92-9AJ
- CONCLUSIONS: The 1 mg norethindrone acetate/5 microg ethinyl estradiol therapy provides significantly better control of vaginal bleeding than conjugated equine estrogens/medroxyprogesterone acetate therapy at all time points investigated in this 12-month study.